Next Article in Journal
MINDIN Exerts Protumorigenic Actions on Primary Prostate Tumors via Downregulation of the Scaffold Protein NHERF-1
Previous Article in Journal
Targeted Metabolomics Identifies Plasma Biomarkers in Mice with Metabolically Heterogeneous Melanoma Xenografts
Previous Article in Special Issue
Global Trends of Latent Prostate Cancer in Autopsy Studies
Open AccessArticle

Prognostic Index for Predicting Prostate Cancer Survival in a Randomized Screening Trial: Development and Validation

1
Unit of Health Sciences, Faculty of Social Sciences, Tampere University, FI-33014 Tampere, Finland
2
UKK Institute for Health Promotion Research, FI-33014 Tampere, Finland
3
Finnish Cancer Registry, FI-00130 Helsinki, Finland
4
Department of Pathology, FIMLAB laboratory services, FI-33014 Tampere, Finland
5
Department of Urology, Helsinki University Hospital, University of Helsinki, FI-00014 Helsinki, Finland
6
Department of Urology, Tampere University Hospital, University of Tampere, FI-33521 Tampere, Finland
7
Department of Public Health, Erasmus MC-University Medical Center Rotterdam, 3015 GD Rotterdam, The Netherlands
8
Department of Biomedical Data Sciences, Leiden University Medical Center, 2333 ZC Leiden, The Netherlands
*
Author to whom correspondence should be addressed.
Cancers 2021, 13(3), 435; https://doi.org/10.3390/cancers13030435
Received: 24 November 2020 / Revised: 8 January 2021 / Accepted: 20 January 2021 / Published: 24 January 2021
(This article belongs to the Collection Urological Cancer)
A prognostic index for predicting survival of localized prostate cancer (PCa) up to 15 and 20 years was developed. The prognostic index performed well for predicting PCa survival among screened and non-screened men. The performance of the prediction model was superior to the European Association of Urology (EAU) risk groups as well as a modified cancer of prostate risk assessment (CAPRA) risk score. We further constructed a simplified risk score in an unscreened population, using the three most relevant predictors. The simplified risk score was applied to predict PCa survival at 10 years from diagnosis to provide more accurate risk estimation as the basis for decision making.
We developed and validated a prognostic index to predict survival from prostate cancer (PCa) based on the Finnish randomized screening trial (FinRSPC). Men diagnosed with localized PCa (N = 7042) were included. European Association of Urology risk groups were defined. The follow-up was divided into three periods (0–3, 3–9 and 9–20 years) for development and two corresponding validation periods (3–6 and 9–15 years). A multivariable complementary log–log regression model was used to calculate the full prognostic index. Predicted cause-specific survival at 10 years from diagnosis was calculated for the control arm using a simplified risk score at diagnosis. The full prognostic index discriminates well men with PCa with different survival. The area under the curve (AUC) was 0.83 for both the 3–6 year and 9–15 year validation periods. In the simplified risk score, patients with a low risk score at diagnosis had the most favorable survival, while the outcome was poorest for the patients with high risk scores. The prognostic index was able to distinguish well between men with higher and lower survival, and the simplified risk score can be used as a basis for decision making. View Full-Text
Keywords: prognostic index; prediction model; prostate cancer; mortality; screening trial prognostic index; prediction model; prostate cancer; mortality; screening trial
Show Figures

Figure 1

MDPI and ACS Style

Neupane, S.; Nevalainen, J.; Raitanen, J.; Talala, K.; Kujala, P.; Taari, K.; Tammela, T.L.J.; Steyerberg, E.W.; Auvinen, A. Prognostic Index for Predicting Prostate Cancer Survival in a Randomized Screening Trial: Development and Validation. Cancers 2021, 13, 435. https://doi.org/10.3390/cancers13030435

AMA Style

Neupane S, Nevalainen J, Raitanen J, Talala K, Kujala P, Taari K, Tammela TLJ, Steyerberg EW, Auvinen A. Prognostic Index for Predicting Prostate Cancer Survival in a Randomized Screening Trial: Development and Validation. Cancers. 2021; 13(3):435. https://doi.org/10.3390/cancers13030435

Chicago/Turabian Style

Neupane, Subas; Nevalainen, Jaakko; Raitanen, Jani; Talala, Kirsi; Kujala, Paula; Taari, Kimmo; Tammela, Teuvo L.J.; Steyerberg, Ewout W.; Auvinen, Anssi. 2021. "Prognostic Index for Predicting Prostate Cancer Survival in a Randomized Screening Trial: Development and Validation" Cancers 13, no. 3: 435. https://doi.org/10.3390/cancers13030435

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop